Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of MVA-NP+M1 plus inactivated influenza vaccine in adults aged 65 years and above
2017-001103-77Phase 2Completed
- Sponsor
- Barinthus Biotherapeutics
- Start
- May 2018
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of VTP-100 in influenza, sponsored by Barinthus Biotherapeutics. Primary endpoint: Number of days with moderate or severe influenza-like symptoms. Started May 2018; status: completed.
02
Drugs
VTP-100
03
Conditions
influenza
Beyond the preview
Go deeper on 2017-001103-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001103-77.